UnitedHealth Group reported stronger-than-expected first-quarter earnings and raised its full-year outlook, signaling improving cost control and early progress in stabilizing performance.
UnitedHealth Group reported stronger-than-expected first-quarter results and raised its full-year profit outlook.
Emerging Pharma Leaders nominations are now open!
Do you know someone who can make tough decisions that continue to face manufacturers? Are they destined to change the future of pharma?
Nominate a colleague with impressive leadership and career intentions – even yourself! – for the Pharmaceutical Executive 2026 Emerging Pharma Leaders Awards.
The move signals early progress in the company’s efforts to stabilize performance after a period of operational and reputational challenges.
UnitedHealth posted an adjusted earnings of $7.23 per share for the quarter, surpassing analyst expectations by a wide margin, while also benefiting from improved government reimbursement rates across its insurance business.1 The company now expects 2026 adjusted earnings-per-share to exceed $18.25, an increase from its prior forecast and ahead of consensus estimates.
Shares rose approximately 7% in premarket trading following the announcement, with gains extending to peers including CVS Health and Humana, reflecting broader investor optimism that margin pressures across the managed care sector may be easing.
The results come as CEO Stephen Hemsley continues to rebuild investor confidence after a turbulent stretch that included rising medical costs, regulatory scrutiny, and leadership disruption.1
Over the past year, the company has taken steps to streamline operations, including exiting certain international businesses and underperforming health plans,
A key focus for investors has been medical cost trends, which have weighed on the sector since mid-2023 amid elevated utilization, particularly in Medicare Advantage populations. UnitedHealth reported a first-quarter medical cost ratio of 83.9%, below analyst expectations of 85.7%, suggesting more effective cost management despite ongoing demand for healthcare services.2
“We actually think we're going to do a little bit better than we anticipated,” said CFO Wayne DeVeydt, while emphasizing a cautious approach to forward guidance. “We like to believe our execution is the primary driver, but we want to see if any of these trends change in April and May.”
The company also noted continued pressure in Medicaid, where shifting enrollment dynamics have left insurers with higher-acuity populations. UnitedHealth expects to lose approximately 1.3 million Medicaid members, though retention trends appear modestly better than anticipated.
Within its Optum division, performance was mixed, as operating income at Optum Health declined 15% year over year to $3.3 billion, reflecting higher medical costs and ongoing investment, as well as a deliberate reduction in less profitable care arrangements.2 The unit has been a focal point for investors following disclosures earlier this year that regulatory and cost challenges could impact performance by as much as $11 billion over a three-year period.
Despite these pressures, revenue growth remained steady across Optum’s segments. Optum Health generated $24.1 billion in revenue, while Optum Rx, the company’s pharmacy benefit manager, reported a 2% increase to $35.7 billion.
Strategically, UnitedHealth continues to reshape its portfolio. During the quarter, the company agreed to acquire Alegeus Technologies, a healthcare payments and technology platform, while divesting its Optum UK business.
It also plans to repurchase at least $2 billion in shares by the end of the second quarter, signaling confidence in its financial position.1
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
